Table 2 Changes of hormone levels in prostate cancer patients treated GnRH antagonist
Pre | 1 w | 2 w | 1 mo | 3 mo | 6 mo | 12 mo | Statistics | |
|---|---|---|---|---|---|---|---|---|
T | p < 0.05 | |||||||
Measurement, ng/dL percentile change | 376.66 ± 161.71 | 19.4 ± 9.11† −94.8% (n = 39) | 11.8 ± 7.13† −96.7% (n = 36) | 10.23 ± 5.09 −97.3% | 10.09 ± 3.98 −97.3% | 10.49 ± 4.52 −97.2% | 10.81 ± 5.36 −97.1% | Pre vs 1 w, 2 w, 1 mo, 3 mo, 6 mo, 12 mo |
DHT | p < 0.05 | |||||||
Measurement, pg/mL percentile change | 442.76 ± 256.68 | 29.95 ± 15.89 −93.2% | 27.09 ± 15.28 −93.9% | 25.30 ± 14.48 −94.3% | 24.12 ± 14.01 −94.6% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
E2 | p < 0.05 | |||||||
Measurement, pg/mL percentile change | 23.58 ± 12.81 | 3.56 ± 2.58 −84.9% | 3.25 ± 2.21 −86.2% | 3.32 ± 2.01 −85.9% | 3.46 ± 2.37 −85.3% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
DHEA-S | p < 0.05 | |||||||
Measurement, μg/dL percentile change | 125.47 ± 62.48 | 104.38 ± 56.03 −16.8% | 103.7 ± 52.52 −17.3% | 104.17 ± 57.03 −17.0% | 95.47 ± 58.23 −23.9% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
DHEA | p < 0.05 | |||||||
Measurement, ng/mL percentile change | 2.50 ± 1.46 | 2.19 ± 1.52 −12.0% | 2.27 ± 1.45 −8.7% | 2.23 ± 1.57 −10.8% | 2.11 ± 1.69 −15.4% | Pre vs 12 mo | ||
A-dione | p < 0.05 | |||||||
Measurement, ng/mL percentile change | 0.715 ± 0.348 | 0.458 ± 0.278 −35.5% | 0.472 ± 0.231 −33.9% | 0.448 ± 0.230 −37.4% | 0.426 ± 0.220 −40.5% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
LH | p < 0.05 | |||||||
Measurement, mIU/mL percentile change | 7.20 ± 7.31 | 0.285 ± 0.385 −96.0% | 0.255 ± 0.306 −96.5% | 0.303 ± 0.355 −95.8% | 0.453 ± 0.479 −93.7% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo | ||
FSH | p < 0.05 | |||||||
Measurement, mIU/mL percentile change | 14.56 ± 14.47 | 0.889 ± 1.100 −93.9% | 0.993 ± 0.100 −93.2% | 1.224 ± 1.135 −91.6% | 1.83 ± 1.424 −87.4% | Pre vs 1 mo, 3 mo, 6 mo, 12 mo |